Signal #144063 · SEC 8-K

$LTGO SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $LTGO filing catalyst

Why did $LTGO trigger an AI stock catalyst alert?

$LTGO triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +0.5/10). Headline: Latigo Biotherapeutics Reports Q3 2026 Net Loss of $20.9M and $401M in Cash. Key points: - Net loss narrowed to $20.9M vs. $24.8M in Q3 2025; R&D spend was $17.5M. - Reported $401.4M in cash and cash equivalents as of Sept 30, 2026. - Phase 3 bunionectomy trial for onzotrigine on track, topline expected in H2 2027.

How did $LTGO stock react after the SEC filing?

After the SEC 8-K for $LTGO, observed market reaction: T0 price $14.04. Past moves do not guarantee future results.

Where can I get real-time $LTGO SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $LTGO via Telegram and the VIP Web Terminal from €10/month.

$LTGO

$LTGO – Latigo Biotherapeutics Reports Q3 2026 Net Loss of $20.9M and $401M in Cash

Latigo Biotherapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $LTGO

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (+0.5 / 10)

Net loss narrowed to $20.9M vs. $24.8M in Q3 2025; R&D spend was $17.5M.
Reported $401.4M in cash and cash equivalents as of Sept 30, 2026.
Phase 3 bunionectomy trial for onzotrigine on track, topline expected in H2 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →